Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors

Expert Review of Neurotherapeutics

Volumn 10, Issue 5, 2010, Pages 703-710

  Avila, Jess ^a,b   Wandosell, Francisco ^a,b   Hernández, Félix ^a,b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Alzheimer's disease; Amyloid peptide; GSK 3; Lithium; Tau

Indexed keywords

AMYLOID BETA PROTEIN; AR A 014418; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; INDIRUBIN; LITHIUM; MALEIMIDE DERIVATIVE; NP 12; TAU PROTEIN; THIADIAZOLIDINONE DERIVATIVE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; COGNITION; DEATH; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; MOOD DISORDER; NEUROFIBRILLARY TANGLE; NONHUMAN; PATHOGENESIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SENILE PLAQUE; TRANSGENICS;

ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MICE; MODELS, MOLECULAR; NEUROFIBRILLARY TANGLES; SENILE PLAQUES; TAU PROTEINS;

EID: 77951875902     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.40     Document Type: Review

References (103)

1. Alzheimer A. [On certain peculiar diseases of old age]. Arch. Psychiatr. Nervenkr. Z. Gesamte Neurol. Psychiatr. 4, 356-386 (1911). • First step in the study of the disease.
2. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MM. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 215 (4537), 1237-1239 (1982). •• Key paper describing the main composition of senile plaques. (Pubitemid 12106486)
3. Masters CL, Multhaup G, Simms G, Pottgiesser J, Martins RN, Beyreuther K. Neuronal origin of a cerebral amyloid: neurofbrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J. 4 (11), 2757-2763 (1985). •• Key paper describing the main composition of senile plaques.
4. Glenner GG, Wong CC. Alzheimer's disease: initial report of the purifcation and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120 (3), 885-890 (1984). (Pubitemid 14104991)
5. Price DL, Sisodia SS. Mutant genes in familial Alzheimer's disease and transgenic models. Annu. Rev. Neurosci. 21, 479-505 (1998). (Pubitemid 28150671)
6. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LL. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskelet al. pathology. Proc. Natl Acad. Sci. USA 83 (13), 4913-4917 (1986). •• Key paper describing phosphorylated tau in Alzheimer's disease (AD). (Pubitemid 16075509)
7. Morishima-Kawashima M, Hasegawa M, Takio K et al. Proline-directed and non-proline-directed phosphorylation of PHF-tau. J. Biol. Chem. 270 (2), 823-829 (1995).
8. Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol. Med. 15 (3), 112-119 (2009).
9. Nishiura C, Takeuchi K, Minoura K et al. Importance of Tyr310 residue in the third repeat of microtubule binding domain for flament formation of tau protein. J. Biochem. 147 (3), 405-414 (2009).
10. Hardy J, Selkoe DD. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (5580), 353-356 (2002). • Main hypothesis for the origin of AD. (Pubitemid 34790756)
11. Murayama O, Tomita T, Nihonmatsu N et al. Enhancement of amyloid b 42 secretion by 28 different presenilin 1 mutations of familial Alzheimer's disease. Neurosci. Lett. 265 (1), 61-63 (1999). (Pubitemid 29210198)
12. Dermaut B, Kumar-Singh S, Engelborghs S et al. A novel presenilin 1 mutation associated with Pick's disease but not β-amyloid plaques. Ann. Neurol. 55 (5), 617-626 (2004). (Pubitemid 38544321)
13. Santacruz K, Lewis J, Spires T et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309 (5733), 476-481 (2005). • Noteworthy paper on the relationship among neurofbrillary tangles (NFTs) and cognitive functions in AD. (Pubitemid 40994688)
14. Avila, J. Tau phosphorylation and aggregation in Alzheimer's disease pathology. FEBS Lett. 580 (12), 2922-2927 (2006). (Pubitemid 44250900)
15. Gomez-Ramos A, Diaz-Hernandez M, Cuadros R, Hernandez F, Avila J. Extracellular tau is toxic to neuronal cells. FEBS Lett. 580 (20), 4842-4850 (2006). (Pubitemid 44286844)
16. Clavaguera F, Bolmont T, Crowther RA et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 11 (7), 909-913 (2009).
17. Embi N, Rylatt DB, Cohen P. Glycogen synthase kinase-3 from rabbit skelet al. muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur. J. Biochem. 107 (2), 519-527 (1980).
18. Woodgett JJ. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 9 (8), 2431-2438 (1990). •• Key paper on the molecular features of glycogen synthase kinase (GSK)-3. (Pubitemid 20218338)
19. Hansen L, Arden KC, Rasmussen SB et al. Chromosomal mapping and mutational analysis of the coding region of the glycogen synthase kinase-3α and b isoforms in patients with NIDDM. Diabetologia 40 (8), 940-946 (1997). (Pubitemid 27316575)
20. Shaw PC, Davies AF, Lau KF et al. Isolation and chromosomal mapping of human glycogen synthase kinase-3α and-3β encoding genes. Genome 41 (5) , 720-727 (1998).
21. Mukai F, Ishiguro K, Sano Y, Fujita SS. Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3β. J. Neurochem. 81 (5), 1073-1083 (2002). (Pubitemid 34809290)
22. Jope RS, Johnson GG. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 29 (2), 95-102 (2004). • Excellent review on GSK-3.
23. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BB. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378 (6559), 785-789 (1995). (Pubitemid 26004411)
24. Nakashima H, Ishihara T, Suguimoto P et al. Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathol. 110 (6), 547-556 (2005). (Pubitemid 41763984)
25. Thornton TM, Pedraza-Alva G, Deng B et al. Phosphorylation by p38 MAPK as an alternative pathway for GSK3β inactivation. Science 320 (5876), 667-670 (2008). • Describes a specifc way to regulate the activity of GSK-3β but not that of GSK-3α. (Pubitemid 351928349)
26. Lochhead PA, Kinstrie R, Sibbet G, Rawjee T, Morrice N, Cleghon V. A chaperone-dependent GSK3β transitional intermediate mediates activation-loop autophosphorylation. Mol. Cell 24 (4), 627-633 (2006). (Pubitemid 350284229)
27. Simon D, Benitez MJ, Gimenez-Cassina A et al. Pharmacological inhibition of GSK-3 is not strictly correlated with a decrease in tyrosine phosphorylation of residues 216/279. J. Neurosci. Res. 86 (3), 668-674 (2008). (Pubitemid 351204481)
28. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. β-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 16 (13), 3797-3804 (1997).
29. Castano Z, Gordon-Weeks PR, Kypta RR. The neuron-specifc isoform of glycogen synthase kinase-3β is required for axon growth. J. Neurochem. DOI: 10.1111/j. 1471-4159.2010.06581.x (2010) (Epub ahead of print).
30. Wu D, Pan W GSK3, a multifaceted kinase in Wnt signaling. Trends Biochem. Sci. 35 (3), 161-168 (2010).
31. Grimes CA, Jope RR. The multifaceted roles of glycogen synthase kinase 3b in cellular signaling. Prog. Neurobiol. 65 (4), 391-426 (2001). • Good review on GSK-3.
32. Uemura K, Kuzuya A, Shimozono Y et al. GSK3β activity modifes the localization and function of presenilin 1. J. Biol. Chem. 282 (21), 15823-15832 (2007). (Pubitemid 47093307)
33. Takashima A, Honda T, Yasutake K et al. Activation of tau protein kinase I/glycogen synthase kinase-3β: By amyloid β peptide (25-35) enhances phosphorylation of tau in hippocampal neurons. Neurosci. Res. 31 (4), 317-323 (1998). (Pubitemid 28446014)
34. Zhang Z, Hartmann H, Do VM et al. Destabilization of β-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature 395 (6703), 698-702 (1998). (Pubitemid 28475966)
35. Baki L, Shioi J, Wen P et al. PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations. EMBO J. 23 (13), 2586-2596 (2004). (Pubitemid 38988230)
36. Munoz-Montano JR, Moreno FJ, Avila J, Diaz-Nido J. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett. 411 (2-3), 183-188 (1997). •• One of the first papers showing the effect of lithium on AD. (Pubitemid 27301451)
37. Alvarez G, Munoz-Montano JR, Satrustegui J, Avila J, Bogonez E, Diaz-Nido J. Lithium protects cultured neurons against β-amyloid-induced neurodegeneration. FEBS Lett. 453 (3), 260-264 (1999). (Pubitemid 29326659)
38. Wang ZF, Li HL, Li XC et al. Effects of endogenous β-amyloid overproduction on tau phosphorylation in cell culture. J. Neurochem. 98 (4), 1167-1175 (2006).
39. Farias GG, Godoy JA, Hernandez F, Avila J, Fisher A, Inestrosa NN. M1 muscarinic receptor activation protects neurons from β-amyloid toxicity. A role for Wnt signaling pathway. Neurobiol. Dis. 17 (2), 337-348 (2004). (Pubitemid 39345789)
40. Avila J, Lucas JJ, Perez M, Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiol. Rev. 84 (2), 361-384 (2004). (Pubitemid 38365487)
41. Meshorer E, Soreq H. Pre-mRNA splicing modulations in senescence. Aging Cell 1 (1), 10-16 (2002).
42. ter Haar E, Coll JT, Austen DA, Hsiao HM, Swenson L, Jain J. Structure of GSK3β reveals a primed phosphorylation mechanism. Nat. Struct. Biol. 8 (7), 593-596 (2001). (Pubitemid 32613006)
43. Dajani R, Fraser E, Roe SM et al. Crystal structure of glycogen synthase kinase 3β: structural basis for phosphate-primed substrate specifcity and autoinhibition. Cell 105 (6), 721-732 (2001). (Pubitemid 32635102)
44. Alonso Adel C, Li B, Grundke-Iqbal I, Iqbal K. Polymerization of hyperphosphorylated tau into flaments eliminates its inhibitory activity. Proc. Natl Acad. Sci. USA 103 (23), 8864-8869 (2006). (Pubitemid 43878109)
45. Noble W, Olm V, Takata K et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38 (4), 555-565 (2003). (Pubitemid 36645031)
46. Sengupta A, Wu Q, Grundke-Iqbal I, Iqbal K, Singh TT. Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5. Mol. Cell. Biochem. 167 (1-2), 99-105 (1997). (Pubitemid 27081337)
47. Nishimura I, Yang Y, Lu B. PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell 116 (5), 671-682 (2004). (Pubitemid 38326726)
48. Amit S, Hatzubai A, Birman Y et al. Axin-mediated CKI phosphorylation of β-catenin at Ser 45, a molecular switch for the Wnt pathway. Genes Dev 16 (9), 1066-1076 (2002). (Pubitemid 34507196)
49. Liu SJ, Zhang AH, Li HL et al. Over activation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory. J. Neurochem. 87 (6), 1333-1344 (2003).
50. Goni-Oliver P, Lucas JJ, Avila J, Hernandez F. N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. J. Biol. Chem. 282 (31), 22406-22413 (2007). • Calpain removes the N-terminal end regulatory domain, activating GSK-3. (Pubitemid 47267365)
51. Kim WY, Wang X, Wu Y et al. GSK-3 is a master regulator of neural progenitor homeostasis. Nat. Neurosci. 12 (11), 1390-1397 (2009).
52. Eom TY, Jope RR. Blocked inhibitory serine-phosphorylation of glycogen synthase kinase-3α/β impairs in vivo neural precursor cell proliferation. Biol Psychiatry 66 (5), 494-502 (2009).
53. Fuster-Matanzo A, de Barreda EG, Dawson HN, Vitek MP, Avila J, Hernandez F. Function of tau protein in adult newborn neurons. FEBS Lett. 583 (18), 3063-3068 (2009). • First indication of a novel role of tau protein in neuron migration.
54. Hong XP, Peng CX, Wei W et al. Essential role of tau phosphorylation in adult hippocampal neurogenesis. Hippocampus DOI: 10.1002/hipo.20712 (2009) (Epub ahead of print).
55. Gomez de Barreda E, Pérez M, Gómez-Ramos P et al. Tau-knock-out mice mice show reduced GSK3 induced hippocampal degeneration and learning defcits. Neurobiol. Dis. 37 (3), 622-629 (2010). • Demonstrates a toxic role for phosphorylated tau.
56. Takashima A, Noguchi K, Sato K, Hoshino T, Imahori K. Tau protein kinase I is essential for amyloid β-protein-induced neurotoxicity. Proc. Natl Acad. Sci. USA 90 (16), 7789-7793 (1993). • Important contribution about the relationship between GSK-3 and tau. (Pubitemid 23250036)
57. Phiel CJ, Wilson CA, Lee VM, Klein PP. GSK-3α regulates production of Alzheimer's disease amyloid-βpeptides. Nature 423 (6938), 435-439 (2003). (Pubitemid 36626994)
58. Perez M, Hernandez F, Lim F, Diaz-Nido J, Avila J. Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J. Alzheimers Dis. 5 (4), 301-308 (2003). •• First paper showing the effect of lithium on tau aggregation in an AD mouse model. (Pubitemid 37411777)
59. Noble W, Planel E, Zehr C et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl Acad. Sci. USA 102 (19), 6990-6995 (2005). (Pubitemid 40675429)
60. Ishiguro K, Omori A, Takamatsu M et al. Phosphorylation sites on tau by tau protein kinase I, a bovine derived kinase generating an epitope of paired helical flaments. Neurosci. Lett. 148 (1-2), 202-206 (1992). (Pubitemid 23007739)
61. Ishiguro K, Shiratsuchi A, Sato S et al. Glycogen synthase kinase 3β is identical to tau protein kinase I generating several epitopes of paired helical flaments. FEBS Lett. 325 (3), 167-172 (1993). • Key paper describing GSK-3 as one of the main tau kinases. (Pubitemid 23186470)
62. Hernandez F, Lucas JJ, Cuadros R, Avila J. GSK-3 dependent phosphoepitopes recognized by PHF-1 and AT-8 antibodies are present in different tau isoforms. Neurobiol. Aging 24 (8), 1087-1094 (2003). (Pubitemid 37487886)
63. Kimura T, Ono T, Takamatsu J et al. Sequential changes of tau-site-specifc phosphorylation during development of paired helical flaments. Dementia 7 (4), 177-181 (1996). (Pubitemid 26276516)
64. Ferrer I, Barrachina M, Puig B. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol (Berl.) 104 (6), 583-591 (2002). (Pubitemid 36075423)
65. Pei JJ, Braak E, Braak H et al. Distribution of active glycogen synthase kinase 3β (GSK-3β) in brains staged for Alzheimer disease neurofbrillary changes. J. Neuropathol. Exp. Neurol. 58 (9), 1010-1019 (1999). (Pubitemid 29441929)
66. Pei JJ, Tanaka T, Tung YC, Braak E, Iqbal K, Grundke-Iqbal I. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J. Neuropathol. Exp. Neurol. 56 (1), 70-78 (1997). (Pubitemid 127470328)
67. Yamaguchi H, Ishiguro K, Uchida T, Takashima A, Lemere CA, Imahori K Preferential labeling of Alzheimer neurofbrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3β and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol (Berl.) 92 (3), 232-241 (1996). (Pubitemid 26278953)
68. Schaffer BA, Bertram L, Miller BL et al. Association of GSK3B with Alzheimer disease and frontotemporal dementia. Arch. Neurol. 65 (10), 1368-1374 (2008).
69. Brandon NJ, Millar JK, Korth C, Sive H, Singh KK, Sawa A. Understanding the role of DISC1 in psychiatric disease and during normal development. J. Neurosci. 29 (41), 12768-12775 (2009).
70. Mao Y, Ge X, Frank CL et al. Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3β/β-catenin signaling. Cell 136 (6), 1017-1031 (2009). • Demonstrated a new way to regulate GSK-3 activity.
71. Jackson GR, Wiedau-Pazos M, Sang TK et al. Human wild-type tau interacts with wingless pathway components and produces neurofbrillary pathology in Drosophila. Neuron 34 (4), 509-519 (2002). (Pubitemid 34628749)
72. Brownlees J, Irving NG, Brion JP et al. Tau phosphorylation in transgenic mice expressing glycogen synthase kinase-3β transgenes. Neuroreport 8 (15), 3251-3255 (1997). (Pubitemid 27461376)
73. Spittaels K, Van den Haute C, Van Dorpe J et al. Neonatal neuronal overexpression of glycogen synthase kinase-3 β reduces brain size in transgenic mice. Neuroscience 113 (4), 797-808 (2002). (Pubitemid 35245250)
74. Li B, Ryder J, Su Y et al. Over expression of GSK3bS9A resulted in tau hyperphosphorylation and morphology reminiscent of pretangle-like neurons in the brain of PDGSK3β transgenic mice. Transgenic Res. 13 (4), 385-396 (2004). (Pubitemid 39182836)
75. Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J. Decreased nuclear β-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice. EMBO J. 20 (1-2), 27-39 (2001). • Animal model to study the role of GSK-3β in different brain areas. (Pubitemid 32099099)
76. Hernandez F, Borrell J, Guaza C, Avila J, Lucas JJ. Spatial learning defcit in transgenic mice that conditionally over-express GSK-3β in the brain but do not form tau flaments. J. Neurochem. 83 (6), 1529-1533 (2002). (Pubitemid 35477491)
77. Engel T, Hernandez F, Avila J, Lucas JJ. Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J. Neurosci. 26 (19), 5083-5090 (2006). (Pubitemid 44315289)
78. Engel T, Goni-Oliver P, Lucas JJ, Avila J, Hernandez F. Chronic lithium administration to FTDP-17 tau and GSK-3β overexpressing mice prevents tau hyperphosphorylation and neurofbrillary tangle formation, but pre-formed neurofbrillary tangles do not revert. J. Neurochem. 99 (6), 1445-1455 (2006). (Pubitemid 44924224)
79. Engel T, Lucas JJ, Gomez-Ramos P, Moran MA, Avila J, Hernandez F. Cooexpression of FTDP-17 tau and GSK-3β in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol. Aging 27 (9), 1258-1268 (2006). (Pubitemid 44088576)
80. Hoefich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JJ. Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation. Nature 406 (6791), 86-90 (2000). (Pubitemid 30460216)
81. Gomez-Sintes R, Hernandez F, Bortolozzi A et al. Neuronal apoptosis and reversible motor defcit in dominantnegative GSK-3 conditional transgenic mice. EMBO J. 26 (11), 2743-2754 (2007). • Mice overexpressing a dominant-negative GSK-3β form show us that extensive GSK-3 inhibition can induce apoptosis. (Pubitemid 46884288)
82. Meares GP, Jope RR. Resolution of the nuclear localization mechanism of glycogen synthase kinase-3, functional effects in apoptosis. J. Biol. Chem. 282 (23), 16989-17001 (2007).
83. Dominguez I, Itoh K, Sokol SS. Role of glycogen synthase kinase 3β as a negative regulator of dorsoventral axis formation in Xenopus embryos. Proc. Natl Acad. Sci. USA 92 (18), 8498-8502 (1995).
84. Zhang YW, Liu S, Zhang X et al. A Functional mouse retroposed gene Rps23r1 reduces Alzheimer's β-amyloid levels and tau phosphorylation. Neuron 64 (3), 328-340 (2009).
85. Klein PS, Melton DD. A molecular mechanism for the effect of lithium on development. Proc. Natl Acad. Sci. USA 93 (16), 8455-8459 (1996).
86. Ryves WJ, Dajani R, Pearl L, Harwood AA. Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites. Biochem. Biophys. Res. Commun. 290 (3), 967-972 (2002). (Pubitemid 34687456)
87. Caccamo A, Oddo S, Tran LX, LaFerla FF. Lithium reduces tau phosphorylation but not Aβ or working memory defcits in a transgenic model with both plaques and tangles. Am. J. Pathol. 170 (5), 1669-1675 (2007). (Pubitemid 47339311)
88. Hampel H, Ewers M, Burger K et al. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebocontrolled, multicenter 10-week study. J. Clin. Psychiatry 70 (6), 922-931 (2009).
89. Bhat R, Xue Y, Berg S et al. Structural insights and biological effects of glycogen synthase kinase 3-specifc inhibitor AR-A014418. J. Biol. Chem. 278 (46), 45937-45945 (2003). (Pubitemid 37432740)
90. Leclerc S, Garnier M, Hoessel R et al. Indirubins inhibit glycogen synthase kinase-3 β and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J. Biol. Chem. 276 (1), 251-260 (2001). (Pubitemid 32050314)
91. Coghlan MP, Culbert AA, Cross DA et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. 7 (10), 793-803 (2000).
92. Martinez A, Alonso M, Castro A, Perez C, Moreno FF. First non-ATP competitive glycogen synthase kinase 3β (GSK-3β:) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem. 45 (6), 1292-1299 (2002). (Pubitemid 34263565)
93. Sereno L, Coma M, Rodriguez M et al. A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol. Dis. 35 (3), 359-367 (2009).
94. Rao K V, Donia MS, Peng J et al. Manzamine B, E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases. J. Nat. Prod. 69 (7), 1034-1040 (2006). (Pubitemid 44252215)
95. Mazanetz MP, Fischer PP. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat. Rev. Drug Discov. 6 (6), 464-479 (2007).
96. Medina M, Castro A. Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic. Curr. Opin. Drug Discov. Devel. 11 (4), 533-543 (2008). (Pubitemid 351950847)
97. Zhong H, Zou H, Semenov MV et al. Characterization and development of novel small-molecules inhibiting GSK3 and activating Wnt signaling. Mol. Biosyst. 5 (11), 1356-1360 (2009).
98. Kimura T, Yamashita S, Nakao S et al. GSK-3β is required for memory reconsolidation in adult brain. PLoS One 3 (10), e3540 (2008).
99. Hooper C, Markevich V, Plattner F et al. Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur. J. Neurosci. 25 (1), 81-86 (2007). (Pubitemid 46096224)
100. Peineau S, Taghibiglou C, Bradley C et al. LTP inhibits LTD in the hippocampus via regulation of GSK3β. Neuron 53 (5), 703-717 (2007). (Pubitemid 46283369)
101. Son H, Yu IT, Hwang SJ et al. Lithium enhances long-term potentiation independently of hippocampal neurogenesis in the rat dentate gyrus. J. Neurochem. 85 (4), 872-881 (2003). (Pubitemid 36578619)
102. Lau KF, Miller CC, Anderton BH, Shaw PP. Molecular cloning and characterization of the human glycogen synthase kinase-3β promoter. Genomics 60 (2), 121-128 (1999). (Pubitemid 29463670)
103. Russ C, Lovestone S, Powell JJ. Identifcation of sequence variants and analysis of the role of the glycogen synthase kinase 3β gene and promoter in late onset Alzheimer's disease. Mol. Psychiatry 6 (3), 320-324 (2001). (Pubitemid 32275679)